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Abstract
Role of RNA structure in pre-mRNA splicing has been implicated for several critical exons associated with
genetic disorders. However, much of the structural studies linked to pre-mRNA splicing regulation are limited
to terminal stem-loop structures (hairpins) sequestering splice sites. In few instances, role of long-distance
interactions is implicated as the major determinant of splicing regulation. With the recent surge of reports of
circular RNA (circRNAs) generated by backsplicing, role of Alu-associated RNA structures formed by long-
range interactions are taking central stage. Humans contain two nearly identical copies of Survival Motor
Neuron (SMN) genes, SMN1 and SMN2. Deletion or mutation of SMN1 coupled with the inability of SMN2
to compensate for the loss of SMN1 due to exon 7 skipping causes spinal muscular atrophy (SMA), one of the
leading genetic diseases of children. In this review, we describe how structural elements formed by both local
and long-distance interactions are being exploited to modulate SMN2 exon 7 splicing as a potential therapy
for SMA. We also discuss how Alu-associated secondary structure modulates generation of a vast repertoire of
SMN circRNAs. This article is part of a Special Issue entitled: RNA structure and splicing regulation edited by
Francisco Baralle, Ravindra Singh and Stefan Stamm.
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Role of RNA structure in pre-mRNA splicing has been implicated for several critical exons 
associated with genetic disorders. However, much of the structural studies linked to pre-mRNA 
splicing regulation are limited to terminal stem-loop structures (hairpins) sequestering splice 
sites. In few instances, role of long-distance interactions is implicated as the major determinant 
of splicing regulation. With the recent surge of reports of circular RNA (circRNAs) generated by 
backsplicing, role of Alu-associated RNA structures formed by long-range interactions are taking 
central stage. Humans contain two nearly identical copies of Survival Motor Neuron (SMN) 
genes, SMN1 and SMN2. Deletion or mutation of SMN1 coupled with inability of SMN2 to 
compensate for the loss of SMN1 due to exon 7 causes spinal muscular atrophy (SMA), one of 
the leading genetic diseases of children. In this review, we describe how structural elements 
formed by both local and long-distance interactions are being exploited to modulate SMN2 exon 
7 splicing as a potential therapy for SMA. We also discuss how Alu-associated secondary 














Alternative pre-mRNA splicing enhances the coding potential of eukaryotic genome by 
generating multiple transcripts from a single gene [1-4]. All human genes with two or more 
exons have potential to be alternatively spliced. Complexity of alternative splicing multiplies 
with the increasing number of exons within a gene. Pre-mRNA splicing can occur in both 
directions, forward and backward [5]. While forward splicing generates linear transcripts, 
including messenger RNAs (mRNAs) and long non-coding RNAs (lncRNAs), backsplicing 
produces circular RNAs (circRNAs) [5-7]. Based on the experimental validations in case of 
Survival Motor Neuron (SMN) gene, a 30-kb long human gene has capability to generate 
hundreds of transcripts if forward and back splicing are appropriately factored [8-11]. Not all 
transcripts generated by alternative splicing are stable due to RNA surveillance mechanisms, 
which preferentially degrade transcripts with premature termination codons (PTCs) and/or other 
suboptimal features [12,13]. Hence, the abundance of transcripts generated by a gene cannot be 
accurately captured. Arrangement of cis-elements on a pre-mRNA coupled with the relative 
expression of transacting factors are the drivers of alternative splicing [14,15]. Depending upon 
the context, similar cis-element may have positive or negative effect on alternative splicing of an 
exon [16,17].  
 
Context of an exon is defined by multiple factors, including size of the exon, strength of 
the splice sites, positioning of cis-elements within the exon and the flanking intronic sequences 
[14-21]. RNA structure adds an important dimension to the context of an exon as it modulates 
accessibility of the cis-elements and shortens the distance between cis-elements located far apart 
[22-28]. In case of backsplicing that generates circRNAs, RNA structure plays a pivotal role in 
bringing the downstream 5 splice site (5ss) in close proximity to the upstream 3ss [29]. RNA 
structure-mediated alternative splicing events are sensitive to the surrounding environment that 
affects structure, including temperature, ionic strength and the interacting molecules [25,30-32]. 
Consequently, RNA structure may serve as a trigger for differential splicing of exons under 
changed environment such as thermal, osmotic and oxidative stress. In living cells splicing is 
coupled to transcription and vice versa [33]. Chromatin structure can influence the context by 
modulating the rate of transcription and consequently determining the outcome of alternative 













through modification of chromatin structure can have effect on the context of an exon as well 
[33]. There is also evidence to suggest that the nascent pre-mRNA structure influences 
transcription and consequently modulates co-transcriptional splicing regulation [36].  
 
Humans have two nearly identical copies of Survival Motor Neuron (SMN) gene: SMN1 
and SMN2 [37]. Both SMN genes code for SMN, an essential protein linked to diverse functions, 
including snRNP assembly, pre-mRNA splicing, transcription, translation, stress granule 
formation, macromolecular trafficking and maintenance of the cytoskeletal dynamics [38-40]. A 
critical C-to-T mutation at the 6th position (C6U substitution in RNA) of exon 7 distinguishes 
SMN2 from SMN1 [41,42]. Although C6U substitution alone is sufficient to trigger SMN2 exon 7 
skipping [41], more than fifty cis-elements and transacting factors have been implicated in 
regulation of SMN exon 7 splicing (Fig.1A). While a complete description of all regulatory 
elements of SMN is beyond the scope of this report, reviews published on this topic over the 
recent years capture how our understanding of SMN exon 7 splicing regulation is continuing to 
evolve [43-46]. The overriding evidence support that the effect of a disease-causing exonic 
mutation (such as C6U substitution within SMN2 exon 7) could be overcome by compensatory 
mutations within both exonic and intronic sequences. In this review, we focus on a structure as a 
modulator of SMN exon 7 splicing.  
 
Due to predominant skipping of SMN2 exon 7, SMN2 contributes very little towards the 
generation of the overall pool of SMN in human cells (Fig. 1B). Consequently, reduction in 
SMN levels due to the loss of SMN1 causes spinal muscular atrophy (SMA), a leading genetic 
disease of children and infants [47]. While degeneration of motor neurons is the first 
manifestation of the disease, peripheral tissues are also affected in SMA [48,49]. In addition, 
based on the severe impairment of male reproductive organ development and male infertility 
observed in mild SMA mouse models, the disease appears to be gender-specific [50-52]. 
Incidentally, testis produces high levels of SMN due to an adult-specific splicing switch from 
exclusion to mostly inclusion of SMN2 exon 7 [50]. The mechanism of this splicing switch 
remains unknown. In general, SMN2 is dispensable for survival of humans. However, testis-
specific switch of SMN2 exon 7 splicing to fulfill the demand for an elevated levels of SMN 













SMN2 during evolution. Considering SMN2 is almost universally present in SMA patients, 
correction of SMN2 exon 7 splicing provides one of the best avenues for SMA therapy.  
 
Nusinersen (SpinrazaTM), the first drug approved by FDA in 2016 for the treatment of 
SMA, acts through correction of SMN2 exon 7 splicing [53,54]. Nusinersen is an antisense 
oligonucleotide (ASO) that sequesters Intronic Splicing Silencer N1 (ISS-N1) located within 
intron 7 (Fig. 1B) [55,56]. Positioned within a complex structural context, ISS-N1 harbors 
multiple cis-elements, including a GC-rich sequence and two hnRNP motifs and a cryptic 5ss,  
Cr1 (Fig. 1A) [57-59]. Two putative TIA1 binding sites are located immediately downstream of 
ISS-N1 (Fig. 1A) [60]. Another cryptic 5ss, Cr2, located 28 nucleotides (nts) downstream of the 
Cr1 falls within the TIA1 binding site (Fig. 1A) [59]. Similar to ISS-N1 targeting ASOs, 
engineered U1 snRNPs (eU1s) annealing to ISS-N1 or sequences in its vicinity also promote 
SMN2 exon 7 inclusion [59,61-63]. It is proposed that the stimulatory effect of ISS-N1 targeting 
ASO is at least in part due to the structural rearrangement at the 5ss of exon 7 [56]. Similar 
mechanism could hold true for the stimulatory effects of eU1s that target ISS-N1 or nearby 
sequences.  In case when the authentic 5ss of exon 7 is mutated, eU1s annealing to ISS-N1 or 
sequences in the vicinity preferentially activate Cr1 [59,63]. Here again, eU1-induced structural 
arrangement could play an important role in bringing Cr1 and the 3ss of intron 7 in close 
proximity. A number of small molecules that modulate SMN2 exon 7 splicing with high 
specificity are at different stages of the pre-clinical and/or clinical development [64-67]. At least 
two of these small molecules are shown to interact with RNA structures within SMN pre-mRNA 
[66,67].  
 
2. Role of local structures formed by exon 7 
As indicated by the results of in vitro structure probing, most of the 54 nts of human SMN exon 7 
is engaged in the formation of RNA secondary structures comprised of two terminal stem loops 
(TSLs) and an internal stem (IS)  (Fig. 2) [68,69]. TSL1 and TSL2 sequester the 3ss and 5ss, 
respectively (Fig. 2) [23]. The IS1 is formed by the central region of exon 7 and intron 6 
sequence (Fig. 2) [23]. Here we discuss the role of all probed structures in modulation of SMN 
exon 7 splicing. Where relevant, we also discuss potential role of the predicted secondary 













2.1 Role of TSL1 
The TSL1 is formed by the first sixteen nucleotides of exon 7 (Fig. 2A) [68,69]. Six of these 
sixteen nucleotides are located in the loop of TSL1; whereas, remaining ten residues form the 
stem. C6U substitution that distinguishes SMN2 from SMN1 is located at the loop-closing 
position and is predicted to increase the stem size of TSL1 from 5-bp to 6-bp duplex (Fig. 2) 
[68,69]. However, the results of enzymatic structure probing showed unpaired nature of 6U, 
suggesting that the stem size of TSL1 is not changed in SMN2 [23]. In this scenario, the 
UAGACA motif created by C6U substitution falls within the loop of TSL1. It has been proposed 
that UAGACA motif serves as a strong binding site for hnRNP A1, a negative regulator of 
SMN2 exon 7 splicing [70]. Hence, UAGACA location within the loop makes this motif highly 
accessible for interactions with hnRNP A1. In case of SMN1, the loop of TSL1 is represented by 
the CAGACA motif that overlaps with CAGACAA motif, which is proposed to interact with 
ASF/SF2, a positive regulator of SMN1 exon 7 splicing [71]. Aside from the loop harboring 
protein-binding motifs, mutations within the stem region of TSL1 promote SMN2 exon 7 
inclusion, suggesting that the entire TSL1 structure is inhibitory [69]. Based on the results of 
extensive point mutations, we concluded that TSL1 is located within an extended inhibitory 
context (Exinct) spanning from the 3rd to 15th positions of exon 7 [69]. An antisense microwalk 
independently validated the presence of Exinct [72]. In particular, ASOs disrupting TSL1 
promoted SMN2 exon 7 inclusion [72]. In vivo selection serves as one of the unbiased methods 
to interrogate the position-specific significance of nucleotide residues in alternative splicing [73]. 
Incidentally, SMN1 exon 7 was the first entire exon subjected to in vivo selection [74]. The 
results of in vivo selection of SMN1 exon 7 supported the presence of Exinct [74]. Of note, 
unlike SMN1 exon 7, SMN2 exon 7 has a strengthened Exinct due to C6U substitution. More 
recently, a machine-learning-based computational analysis validated the findings of in vivo 
selection and suggested that the Exinct-like motifs created by genetic mutations are associated 
with genetic diseases [75].  
 
Employing in vitro Selective 2-Hydroxyl Acylation analyzed by Primer Extension 
(SHAPE)-based RNA structure probing method, an alternative TSL structure was proposed at 
the location previously designated as TSL1 (Fig. 2A) [23, 66]. Disparity between these two 













structure probing [23,66]. Also, differences in structures could be due to different lengths of 
sequences analyzed for in vitro structure probing. Interestingly, only a part of the alternative 
structure at the beginning of exon 7 was found to be preserved when sequences were analyzed by 
in-cell SHAPE structure probing method [66]. Future studies will determine if RNA structures 
adopt different confirmations based on the presence of the exon 7-interacting factors in the cell. 
 
2.2 Role of TSL2 
The TSL2 is the first experimentally validated structure of SMN pre-mRNA (Fig. 2) [23]. TSL2 
is formed by a 19-nt long sequence encompassing the last seventeen and the first two residues of 
exon 7 and intron 7, respectively. Based on the results of in vivo selection of the entire exon 7, 
TSL2 encompasses an inhibitory region called the “3-Cluster” [73,74]. Antisense microwalk as 
well as the machine-learning-based computational analysis validate the inhibitory nature of the 
3-Cluster [72,75]. Supporting the negative effect of TSL2, point mutations that abrogate TSL2 
stimulate SMN2 exon 7 inclusion (Fig. 2C) [23]. Conversely, compensatory mutations that 
restore TSL2 promote SMN2 exon 7 skipping (Fig. 2C) [23]. Located within TSL2, wild-type A 
residue at the last position (54A) of exon 7 has been determined to be highly inhibitory [74]. 
Consistently, an A-to-G substitution (A54G) at the last position of exon 7 fully restores SMN2 
exon 7 inclusion. The stimulatory effect of A54G substitution happens to be so pronounced that 
absence of most known positive cis-elements within exon 7 is tolerated [74]. A54G substitution 
is predicted to destabilize TSL2 as it changes the canonical U-A base pair into wobble U-G base 
pair. In addition, 54G increases the base pairing between endogenous U1 snRNA and the 5ss of 
exon 7. An eU1 with extended base-pairing with 5ss of exon 7 fully restored SMN2 exon 7 
inclusion [23]. These findings support that the poor recruitment of U1 snRNP is one of the 
limiting factors for SMN2 exon 7 splicing. Recently, a small compound PK4C9 that promotes 
SMN2 exon 7 inclusion, has been shown to interact with TSL2 [67]. Based on this interaction, 
authors propose that PK4C9 favors recruitment of U1 snRNP through remodeling of the 5ss of 
exon 7.  
 














Based on the enzymatic structure probing, IS1 is a 10-bp long duplex in the middle of SMN exon 
7 (Fig. 2A) [23]. While the purine-rich 3-strand of IS1 is provided by exon 7, the pyrimidine-
rich 5-strand of IS1 comes from intron 6. IL1, a 4-nt (ACAG) internal loop, bridges the 5-strand 
of IS1 with the 5-strand of TSL1 (Fig. 2A). IL2, a 6-nt purine-rich (AAAAG) internal loop, 
bridges the 3-strand of TSL1 with the 3-strand of IS1 (Fig. 2A). IL3, another 5-nt internal loop, 
bridges the 3-strand of IS1 with the 5-strand of TSL2 (Fig. 2A). Based on the results of in vivo 
selection, sequences involved in the formation of IL2, IS1 and IL3 appear to be stimulatory [74]. 
Incidentally, IL2 overlaps with the binding site of Tra2-1, which recruits other factors to exon 7 
(Fig. 1A). List of factors interacting with exon 7 is continuing to grow, although no effort has yet 
been made to associate these interactions with specific structures. It is likely that the single 
stranded regions, including IL2 and IL3 provide primary binding sites for positive regulators. 
Supporting this argument, mutations within either IL2 or IL3 have been found to promote SMN1 
exon 7 skipping [74].  
 
Unlike enzymatic structure probing, results of a recent in vitro chemical structure probing 
by SHAPE revealed a shorter IS1 (Fig. 2B) [23,66]. Further, findings of in vitro SHAPE showed 
different structural context upstream and downstream of IS1. However, results of in cell SHAPE 
only partially validated the structural context revealed by in vitro SHAPE. Interestingly, a small 
compound, SMN-C3, that stimulates SMN2 exon 7 inclusion has been proposed to interact with 
IS1. However, this interaction is proposed to be modulated by protein factor(s) [66].  
 
3. Role of structural context of intron 7 
Secondary structure of SMN2 intron 7 deduced from the chemical structure probing was reported 
in 2013 (Fig. 3) [27]. The key findings of the probed secondary structure are the presence of 
internal stems formed by unique long-distance interactions (LDIs). Here we describe functional 
significance of some of these LDIs and as well as other structures formed by intron 7.   
 
3.1 Role of ISTL1 
Internal stem formed by the long-distance interaction 1 (ISTL1) is a unique intra-intronic 
structure located within intron 7 [27]. The two strands of the 8-bp ISTL1 are separated from each 













5-strand of ISTL1 encompasses half of the GC-rich motif that has been confirmed to be an 
effective target for a short (8-mer) ASO [57,76]. The last base of the 5-strand of ISTL1 is a C 
residue located at the 10th intronic position (10C), which also happens to be the first residue of the 
15-nt long ISS-N1 [27]. The significance of 10C first emerged when two 14-nt long ASOs, F14 
and L14, targeting ISS-N1 produced opposite effects on SMN2 exon 7 splicing [18]. While F14 
sequestered the first 14 residues (including 10C) of ISS-N1 and promoted exon 7 inclusion, L14 
sequestered the last 14 residues (excluding 10C) of ISS-N1 and promoted exon 7 skipping [18]. 
Results were validated using ASOs with two different chemistries (locked nucleic acid and 2O-
methyl modifications), ruling out any chemistry-specific effect [18]. Subsequent experiments 
confirmed that F14 destabilizes ISTL1 due to sequestration of 10C, whereas, L14 stabilizes 
ISTL1 due to formation of a duplex with the remainder of the ISS-N1 sequence. Supporting this 
argument, deletion of deep intronic sequences encompassing the 3-strand of ISTL1 eliminated 
the negative effect associated with L14 [27]. Also, increasing the length of ISTL1 duplex 
substantially enhanced the skipping of SMN2 exon 7. These results provided one of the rarest 
examples of how a single nucleotide shift in the annealing position of an ASO could flip the 
effect on splicing. Findings also suggested that the effect of an ISS-N1-annealing  ASO may not 
be due to the displacement of the negative factor(s) (hnRNP A1/A2) only, it could also be due to 
the change in structural context upstream and/or downstream of the ASO annealing position. 
While ISTL1 is the first validated regulatory structure formed by an LDI in the context of a 
human genetic disease, a similar structure in intron 3 of Proteolipid Protein 1 (PLP1) gene has 
been implicated in Pelizaeus-Merzbacher disease (PMD) [77].  
 
3.2 Role of other ISTLs 
In addition to ISTL1, additional structures formed by LDIs within intron 7 include ISTL2, ISTL3 
and ISTL4  (Fig. 3) [27]. Two strands of ISTL2, ISTL3 and ISTL4 are separated from each other 
by 226, 85 and 55 nts, respectively. Similar to ISTL1, ISTL2 and ISTL3 exert negative effect on 
SMN2 splicing, although the effect is not as pronounced as in case of ISLT1. The negative effect 
of ISTL2 could at least in part be attributed to the sequestration of TIA1 binding site located 
immediately downstream of the ISS-N1. Interestingly, a continuous intronic sequence, termed 
ISS-N2, provides the 3-strands of ISTL1, ISTL2 and ISTL3. Deletion or an ASO-mediated 













ISTL1, ISTL2 and ISTL3, the significance of ISTL4 in exon 7 splicing regulation has not yet 
been established.   
 
3.3 Other structures within intron 7 
Results of structure probing supported the formation of several TSLs, ILs and bulges (Fig. 3) 
[27]. Significance of some of these structures could be inferred from the location of the critical 
cis-elements within these structures. For instance, one of the putative hnRNP A1 binding sides 
within ISS-N1 is located within an IL. This loop also harbors four of the eight residues of the 
GC-rich motif that serves as the target for the shortest ASO. Presence of this loop makes ISS-N1 
and GC-rich sequence highly accessible for targeting by ASO. Other putative hnRNP A1 motif 
associated with ISS-N1 is sequestered within TSL3, which also locks one of the TIA1 binding 
sites located downstream of the ISS-N1. It is likely that the stimulatory effect of the ISS-N1-
targeting ASO is linked at least in part to freeing of the TIA1 motif. Sequences downstream of 
ISTL4 form two TSLs, TSL6 and TSL7. Deletion of intron 7 sequences encompassing TSL6 and 
TSL7 moderately stimulated SMN2 exon 7 inclusion [27]. Future studies will determine if these 
and other structures within intron 7 play critical role in regulation of exon 7 splicing.  
 
4. Role of RNA structure in backsplicing  
Primate-specific Alu elements are the most abundant short interspersed nuclear elements 
(SINEs) totaling more than one million copies and accounting for ~11% of the human genome 
[78,79]. Surprisingly, a whopping 39% sequence of human SMN genes are represented by Alu 
elements as inverted repeats in the intronic regions [80]. Presence of inverted Alu repeats results 
in formation of double stranded structures that are conducive for the generation of circRNAs 
through backsplicing [81,82]. Indeed, a recent report confirmed the existence of a large 
repertoire of circRNAs generated from SMN genes (Fig. 4) [11]. Based on the nature of exons, 
SMN circRNAs are broadly categorized into four types [11]. While type 1 circRNAs harbor one 
or more of the early exons (exons 1 through 4), type 2 circRNAs harbor middle exons in addition 
to early exons (exons 1 through 7).  Some of the type 1 circRNAs contain novel exons derived 
from sequences within intron 1. Type 3 circRNAs harbor the 3-terminal exons with or without 
upstream exons. Some of the type 3 circRNAs also contain one or more of the four novel exons 













circRNAs are generated by a combination of backsplicing and trans-splicing, such that one or 
more exons in these circRNAs originate from other genes. Overall, more than fifty SMN 
circRNAs are universally produced in all cell types examined, with type 1 circRNAs being the 
most predominant [11]. All SMN circRNAs are generated by backsplicing from canonical splice 
sites. Both SMN1 and SMN2 generate circRNAs with near equal frequencies. Most common type 
1 circRNAs produced by SMN are C2A-2B-3-4, C2B-3-4 and C3-4 (Fig. 4). These three 
circRNAs share the same 5ss of exon 4 suggesting a random pairing between the 5ss of exon 4 
with the 3ss of any of the upstream exons 2A, 2B and 3. Predicted secondary structures support 
such pairing through RNA:RNA duplex formation between sequences at the 5ss of exon 4 and 
the 3ss of the upstream exons (Fig. 4A) [11]. C5-6 is the predominant circRNA among type 2 
SMN circRNAs (Fig. 4) [11]. Formation of C5-6 is likely to be facilitated by inverted Alu repeats 
that are predicted form secondary structures bringing the 5ss of exon 6 and the 3ss of the exon 5 
in close proximity (Fig. 4A). Among type 3 circRNAs of SMN, C6-7-8A and C6-7-8A-9tr1-10 
are the most common. Here again, generation of type 3 circRNAs is likely facilitated by Alu-
associated secondary structures that bring the 3ss of exon 6 in close proximity with 5ss of any 
of the downstream exons (Fig. 4B). Type 4 circRNAs of SMN are generated by incorporation 
exonic sequences from the neighboring Alu-rich genes, including ERBIN and SERF1 [11]. 
 
Generation of SMN circRNAs appears to be a posttranscriptional event, as suppression of 
transcription elongation had no appreciable effect on the relative abundance of SMN circRNAs. 
At the same time, depletion of DHX9, an RNA helicase that specifically unwinds Alu-associated 
secondary structures, enhanced expression of several SMN circRNAs, including C3-4, one of the 
most predominant circRNAs of SMN [11]. Interestingly, depletion of DHX9 also promoted 
skipping of exons 3 and 4 in various combinations, suggesting that the C3-4 is generated from 
intronic lariats harboring these exons. Considering the 5ss of exon 4 is used to generate several 
circRNAs, including C2A-2B-3-4, C2B-3-4 and C3-4, an enhanced expression of C3-4 under the 
DHX9-depleted conditions consequently led to decreased expression of C2A-2B-3-4 and C2B-3-
4. These findings also suggested that the base pairing between inverted Alu elements located 
upstream and downstream of exons 3 and 4, respectively, is under the control of DHX9.  Many 
of the types 2 and 3 circRNAs showed elevated expressions under the conditions of depleted 













region of SMN pre-mRNA are also under the control of DHX9 [11]. Future studies will 
determine the role of specific secondary structures that are primary drivers for the generation of 
SMN circRNAs.   
 
6. Conclusions 
Generation of mature RNAs, including mRNAs, lncRNAs and circRNAs requires an accurate 
removal of introns during pre-mRNA splicing. Information to remove an intron is distributed 
among cis-elements located within both intronic and exonic sequences. Studies conducted for 
SMN pre-mRNA splicing regulation are instructive in suggesting that a large part of essential 
information for intron removal is locked into structural elements. The inhibitory structural 
context is one of the primary causes of SMN2 exon 7 skipping linked to SMA. The currently 
approved drug, Spinraza, works at least in part through abrogation of the inhibitory structural 
context at the 5ss of exon 7. Many of the small compounds that have recently shown promise for 
SMA therapy appear to also work through modulation of RNA structure at the 5ss of exon 7. A 
vast repertoire of the newly reported SMN circRNAs are generated through structural elements 
abundantly present within Alu-rich SMN. While functions of SMN circRNAs are not yet clear, 
generation of these circRNAs come at the expense of linear transcripts required to produce SMN, 
an essential protein involved in multiple aspects of RNA metabolism. Future studies will 
determine how transacting factors and structural elements collaborate to maintain a fine balance 
between linear transcripts and circRNAs generated by SMN.  
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Figure 1.  Regulation of SMN exon 7 splicing. (A) Diagrammatic representation of intronic and 
exonic cis-elements as well as trans-acting factors that modulate SMN exon 7 splicing. Upper-
case letters signify exonic sequences, small-case letters, intronic sequences. Exons and introns 
are also shown as colored boxes and lines, respectively. Numbering of nucleotides, neutral and 
positive, starts from the first exonic and intronic position, respectively. The 5 and 3 splice sites 
(5ss and 3ss) are indicated by arrows. Cr1 and Cr2 represent cryptic 5 splice sites recently 
reported [59]. Negative and positive regulators of exon 7 splicing are indicated by (-) and (+), 
respectively. For details see [28,46]. (B) Effect of SpinrazaTM on SMN2 exon 7 splicing. Exons 
are represented by colored boxes, introns by lines. First 27 nts of intron 7 with highlighted ISS-
N1 element are given. Annealing positions of SpinrazaTM to ISS-N1 target are shown. SMN2 pre-
mRNA splicing results in predominant skipping of exon 7 in mRNA (SMN2Δ7) and production 
of truncated SMN protein (SMNΔ7). Sequestration of ISS-N1 by SpinrazaTM promote SMN2 
exon 7 inclusion (SMN2FL) and as a consequence increases levels of full-length SMN protein 
(SMN). 
 
Figure 2. Local structures formed by SMN exon 7 and adjacent upstream/downstream intronic 
sequences. Interactions of small exon 7-splicing modifying compounds with a local structure. 
(A) Secondary structure of SMN2 exon 7 and its surrounding intronic sequences derived from 
enzymatic structure probing [23]. Existence of TSL2 and its effect on exon 7 splicing was also 
confirmed by mutational analysis. Intron 6 and intron 7 sequences are shown in small-case green 
and blue letters, respectively. Exon 7 sequence is shown in upper-case black letters. Numbering 
of nucleotides, neutral, positive and negative, starts from the first position in exon 7, first 
position of intron 7 and the last position in intron 6, respectively. The splice sites of exon 7 are 
indicated by the red arrows. IS1 structure is boxed. Nucleotides in magenta indicate site-specific 
mutations, single and compensatory, used to confirm the existence of TSL2 and its effect on 
exon 7 splicing [23]. Abbreviation: IL, internal loop; IS, internal stem; TSL, terminal stem loop. 
(B) Interactions of a small exon 7-splicing modifying compound, SMN-C3, with a local 
structure. Secondary structure of SMN2 exon 7 and its surrounding intronic sequences was 













in (A). Chemical structure of the small compound, SMN-C3, that increases inclusion of exon 7 is 
shown. Binding site of SMN-C3 (in the context of a double strand) is highlighted with red box. 
Residues, whose sensitivity to a structure probing agent, NAI, is increased and decreased upon 
SMN-C3 binding are highlighted in a pink and a blue circle, respectively [66]. (C) Interactions of 
a small exon 7-splicing modifying compound, PK4C9, with TSL2 structure. Upper-case letters 
signify exonic sequence, small-case letters in blue, intron 7 sequence. Nucleotides in red indicate 
site-specific mutations, single and double, used to confirm the effect of destabilization or 
stabilization TSL2 on exon 7 splicing. The 5ss of exon 7 is indicated by the red arrows. 
Chemical structure of PK4C9 is shown. In the lower panel PK4C9 is represented as a red star. 
Upon PK4C9 binding to TSL2, several residues at the base of the stem highlighted with pink 
circles form hydrogen bonds, hydrophobic interactions or stack with the compound [67]. These 
interactions destabilize TSL2 and increase the accessibility of the 5ss. In addition, binding of 
PK4C9 to TSL2 stabilizes the triloop of this RNA structure.  
 
Figure 3. Secondary structure of SMN intron 7. (A) SHAPE-derived structure of intron 7 [27]. 
The structure is based on combined probing results obtained with multiple extension primers. An 
exon 7/intron 7 junction as well as the 5ss are indicated. Exon 8 is represented by a green box. 
Numbering of nucleotides, neutral and negative, starts from the first position of intron 7 and the 
last position of exon 7, respectively. Binding sites of hnRNP A1/A2 and TIA1 are highlighted in 
pink and green, respectively. Residues with normalized 1M7 reactivity > 0.5 are marked with 
large circles, while residues with normalized 1M7 reactivity between 0.3 and 0.5 are indicated 
with small circles. Broken lines indicate potential base-pairing. Positions corresponding to 
Reverse Transcriptase (RTase) falloffs are marked with “F”. Residues in red constitute a region 
whose structure was not determined due to RTase fall off. Abbreviations: ISTL, internal stem 
formed by a long-distance interaction; LS1, long-distance interaction site 1; TSL, terminal stem-
loop; ISS-N2, intronic splicing silencer 2. (B) Site-specific mutations in ISTL1 and adjacent 
regions that effect this structure and cause changes in a pattern in exon 7 splicing with/without 
antisense oligonucleotides [27]. Arrows and letters in red indicate positions and identities of 
mutations, single and compensatory, that break (when single) and restore (when combined) 
ISTL1 structure. Arrows and letters in green indicate positions and identities of mutations deep 













Figure 4. Repertoire of circRNAs generated from the SMN genes. (A) Diagrammatic 
representation of circRNAs identified using primers that anneal to exons 2a, 2b, 3, 4 and 5. A 
genomic overview of the SMN gene layout is given. Exons are indicated by colored shapes, 
introns by lines. Exon sizes are given using numbers in black located below exons, intron sizes 
are shown using numbers in grey located above introns. A newly identified 5ss within exon 8 is 
indicated with black arrow. Colored arrows show canonical backsplicing events. Arrow 
thickness reflects the estimated prevalence of each event. Schematic of the likely role of the Alu-
associated secondary structures in the generation of the most abundant types 1 and 2 circRNAs 
are given (diagram not to the scale). (B) Diagrammatic representation of circRNAs identified 
using primers that anneal to exons 6, 6b, 7 and 8. A genomic overview of the 3 portion of the 
SMN gene layout is given. Labeling and color coding are the same as in (A). Schematic of the 
likely role of the Alu-associated secondary structures in the generation of the most abundant type 
3 circRNAs are given (diagram not to the scale). 
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